Legend Biotech CEO to Present Latest Updates at J.P. Morgan Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy LEGN?
Source: Globenewswire
- Conference Announcement: Legend Biotech's CEO, Dr. Ying Huang, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, at 9:00 AM PT, which is expected to attract attention from investors and other stakeholders.
- Live Webcast: The presentation will be available via a live webcast on Legend's Investor Relations page, with a replay accessible approximately 48 hours post-event, ensuring that investors unable to attend live can still access critical information.
- Company Scale: With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company, focusing on innovations that transform cancer care, particularly in the CAR-T cell therapy sector.
- Product Development: The company's CARVYKTI®, developed in collaboration with Johnson & Johnson as a one-time treatment for relapsed or refractory multiple myeloma, showcases its leadership in cell therapy and positions it to drive further innovations in its pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 16.800
Low
48.00
Averages
68.10
High
90.00
Current: 16.800
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
EEMA Stock Price Fluctuation and ETF Dynamics
- Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
See More
Genscript Biotech Reports 61.4% Revenue Growth Year-Over-Year
- Significant Revenue Growth: Genscript Biotech Corp (GNNSF) reported a 61.4% year-over-year revenue increase to $959.5 million, primarily driven by its gene-to-protein platform, which accounted for 65% of total revenue growth, showcasing the company's strong market performance and competitiveness.
- Profitability Improvement: Adjusted net profit reached nearly $230 million, despite a $398.1 million impairment loss from its investment in Legend Biotech, indicating ongoing efforts to manage investment risks and improve overall financial health.
- Market Expansion Success: North American and European markets contributed 38% of total revenue, reflecting the effectiveness of Genscript's global expansion strategy, which lays a solid foundation for future growth, particularly driven by strong demand in the life sciences sector.
- Sustainability Progress: The company made significant strides in sustainability, receiving an upgraded ESG rating and inclusion in the FTSE for Good Index Series, demonstrating its commitment to social responsibility and environmental protection, which can enhance brand image and market recognition.
See More
Analysis of MCHI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The MCHI ETF has a 52-week low of $44.71 and a high of $67.37, with the latest trade at $58.77, indicating relative stability and investor confidence in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the underlying holdings of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling those assets.
See More
Legend Biotech Q4 Earnings Miss Expectations with Revenue Growth
- Earnings Performance: Legend Biotech reported a Q4 non-GAAP EPS of $0.01, missing expectations by $0.18, indicating pressure on profitability that could affect investor confidence.
- Revenue Growth Shortfall: The company reported revenue of $306.3 million, a 64.2% year-over-year increase, yet it fell short of expectations by $3.91 million, suggesting that despite significant growth, market demand did not fully meet projections.
- Strong Cash Reserves: As of December 31, 2025, Legend Biotech had approximately $949 million in cash and cash equivalents, providing a solid financial foundation for future R&D and market expansion efforts.
- Market Outlook Analysis: Despite the disappointing earnings report, the growth of Carvykti is bolstered by FDA regulatory support, which may drive a recovery in the company's performance, particularly in the multiple myeloma treatment sector.
See More
Legend Biotech to Announce Q4 Earnings on March 10
- Earnings Announcement: Legend Biotech (LEGN) is set to announce its Q4 earnings on March 10 before market open, with a consensus EPS estimate of $0.19, reflecting a substantial year-over-year increase of 218.8%, indicating a significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $310.21 million, representing a 66.3% year-over-year growth, which will further solidify the company's market position in the biotechnology sector, particularly driven by the Carvykti product.
- Performance Beat Record: Over the past two years, LEGN has beaten EPS estimates 63% of the time and revenue estimates 50% of the time, demonstrating the company's stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions but two downward adjustments, while revenue estimates experienced one upward revision and five downward adjustments, indicating a cautious market sentiment regarding the company's future performance.
See More
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
EEMA Stock Price Fluctuation and ETF Dynamics
- Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
See More
Genscript Biotech Reports 61.4% Revenue Growth Year-Over-Year
- Significant Revenue Growth: Genscript Biotech Corp (GNNSF) reported a 61.4% year-over-year revenue increase to $959.5 million, primarily driven by its gene-to-protein platform, which accounted for 65% of total revenue growth, showcasing the company's strong market performance and competitiveness.
- Profitability Improvement: Adjusted net profit reached nearly $230 million, despite a $398.1 million impairment loss from its investment in Legend Biotech, indicating ongoing efforts to manage investment risks and improve overall financial health.
- Market Expansion Success: North American and European markets contributed 38% of total revenue, reflecting the effectiveness of Genscript's global expansion strategy, which lays a solid foundation for future growth, particularly driven by strong demand in the life sciences sector.
- Sustainability Progress: The company made significant strides in sustainability, receiving an upgraded ESG rating and inclusion in the FTSE for Good Index Series, demonstrating its commitment to social responsibility and environmental protection, which can enhance brand image and market recognition.
See More
Analysis of MCHI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The MCHI ETF has a 52-week low of $44.71 and a high of $67.37, with the latest trade at $58.77, indicating relative stability and investor confidence in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the underlying holdings of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling those assets.
See More
Legend Biotech Q4 Earnings Miss Expectations with Revenue Growth
- Earnings Performance: Legend Biotech reported a Q4 non-GAAP EPS of $0.01, missing expectations by $0.18, indicating pressure on profitability that could affect investor confidence.
- Revenue Growth Shortfall: The company reported revenue of $306.3 million, a 64.2% year-over-year increase, yet it fell short of expectations by $3.91 million, suggesting that despite significant growth, market demand did not fully meet projections.
- Strong Cash Reserves: As of December 31, 2025, Legend Biotech had approximately $949 million in cash and cash equivalents, providing a solid financial foundation for future R&D and market expansion efforts.
- Market Outlook Analysis: Despite the disappointing earnings report, the growth of Carvykti is bolstered by FDA regulatory support, which may drive a recovery in the company's performance, particularly in the multiple myeloma treatment sector.
See More
Legend Biotech to Announce Q4 Earnings on March 10
- Earnings Announcement: Legend Biotech (LEGN) is set to announce its Q4 earnings on March 10 before market open, with a consensus EPS estimate of $0.19, reflecting a substantial year-over-year increase of 218.8%, indicating a significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $310.21 million, representing a 66.3% year-over-year growth, which will further solidify the company's market position in the biotechnology sector, particularly driven by the Carvykti product.
- Performance Beat Record: Over the past two years, LEGN has beaten EPS estimates 63% of the time and revenue estimates 50% of the time, demonstrating the company's stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions but two downward adjustments, while revenue estimates experienced one upward revision and five downward adjustments, indicating a cautious market sentiment regarding the company's future performance.
See More
